Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes

Simona Sica, Fabio Efficace, Franco Mandelli, Giuseppe Avvisati, Francesco Cottone, Felicetto Ferrara, Eros Di Bona, Giorgina Specchia, Massimo Breccia, Alessandro Levis, Olimpia Finizio, Maria Grazia Kropp, Giuseppe Fioritoni, Elisa Cerqui, Marco Vignetti, Sergio Amadori, Richard F. Schlenk, Uwe Platzbecker, Francesco Lo-Coco

Risultato della ricerca: Contributo in rivistaArticolo in rivista

56 Citazioni (Scopus)

Abstract

A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid (ATRA) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed, low- or intermediate-risk acute promyelocytic leukemia (APL). Here, we report health-related quality-of-life (HRQOL) results.
Lingua originaleEnglish
pagine (da-a)3406-3412
Numero di pagine7
RivistaJournal of Clinical Oncology
Volume32
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • allogeneic

Fingerprint

Entra nei temi di ricerca di 'Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes'. Insieme formano una fingerprint unica.

Cita questo